DBV Technologies Files 2026 Half-Year Report and Schedules Second Quarter Financial Results Conference Call
核心洞察
DBV Technologies filed its 2026 Half-Year Report with the French market authority (AMF) for the semester ended June 30, 2026.
The company will host a conference call and live webcast on July 16, 2026, at 5:00 p.m. ET to review second quarter 2026 financial results and provide a business update.
DBV Technologies is a late-stage biopharmaceutical company developing the VIASKIN® patch for food allergies (搜索), with ongoing trials in peanut-allergic toddlers and children.
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, announced on July 16, 2026, the filing of its Half-Year Report for the semester ended June 30, 2026, with the French market authority, the Autorité des Marchés Financiers (AMF). Concurrently, the company confirmed it will host an investor conference call and live audio webcast on the same day at 5:00 p.m. ET to review its second quarter 2026 financial results and provide a business update.
The 2026 Half-Year Report is available for consultation or download from the company's website in the Investors/Financial Information section, as well as on the AMF website, in French only.
Advancing Food Allergy Treatment with VIASKIN® Patch Technology
DBV Technologies is focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies (搜索), which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children, representing a significant unmet medical need.
Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT represents a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergens, leveraging the skin's immune tolerizing properties.
Ongoing Clinical Programs
The company's food allergy programs include ongoing clinical trials of the VIASKIN® Peanut Patch in two distinct pediatric populations: peanut-allergic toddlers aged 1 through 3 years and children aged 4 through 7 years. DBV Technologies is committed to transforming the care of people with food allergies (搜索) through these development efforts.
Corporate Information
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, New Jersey. The company's ordinary shares are traded on segment B of Euronext Paris, and its American Depositary Shares (ADSs), each representing five ordinary shares, are traded on the Nasdaq Capital Market.
Interested participants may access the July 16 conference call via teleconferencing at +1-877-344-8082 (United States) or +1-213-992-4618 (International), with a live webcast available on the Events section of the company's website.